Drug Database
ES

escitalopram + clonazepam (Citapure Forte)

✓ Approved

A. N. Pharmacia Laboratories · GABRA1 · Small Molecule

What is escitalopram + clonazepam?

escitalopram + clonazepam is a small molecule developed by A. N. Pharmacia Laboratories. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesCitapure Forte
CompanyA. N. Pharmacia Laboratories
Drug ClassSmall Molecule
Molecular TargetGABRA1, GABRA2, GABRA3, GABRA4, SLC6A4
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, A. N. Pharmacia Laboratories

Mechanism of Action

Molecular Targets

escitalopram + clonazepam acts on 5 molecular targets:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (ECA4, EJM)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (EIEE78, DEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
SLC6A4solute carrier family 6 member 4 (SERT1, 5-HTTLPR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

escitalopram + clonazepam is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersBipolar I disorder✓ Approved
Psychiatric disordersGeneralised anxiety disorder✓ Approved

Related Research Articles

PubMedCase reports in pediatrics2026-07-25

Seven-Year Longitudinal Respiratory Morbidity in Ohtahara Syndrome: A Case Report Emphasizing Integrated Airway and Seizure Care in a Resource-Limited Setting.

Abualhommos Fadi F, Hattab Moath M, Samara Masara M, Suleiman Mahmoud M et al.

Ohtahara syndrome (OS) features neonatal-onset tonic spasms with suppression-burst EEG, high early mortality, and evolution to other epileptic encephalopathies. Respiratory complications are frequent yet underdescribed longitudinally. We followed a female with neonatal-onset OS and suppression-burst EEG to the age of seven. Despite combination antiseizure therapy (phenobarbital, levetiracetam, vigabatrin, and clonazepam), she had breakthrough events and severe developmental impairment. Between the ages 1 and 7 years, she experienced ≥ 15 documented hospitalizations for recurrent bronchopneumonia, frequently with hypoxemia requiring supplemental oxygen; several episodes were accompanied by seizure exacerbations and clinical aspiration or choking events. Admissions were managed with supportive respiratory care (oxygen, bronchodilators, and corticosteroids when indicated) and broad-spectrum antimicrobials alongside ongoing seizure management, enabling survival to school age in a resource-limited context. In OS, respiratory complications, often driven by aspiration risk and impaired airway clearance, can become a dominant source of morbidity and should be addressed with the same priority as antiseizure therapy. We highlight practical pillars for long-term care: proactive infection prevention and early treatment pathways; aspiration-risk assessment with feeding/swallow support when feasible; airway-clearance planning with bronchodilator trials during illnesses; judicious corticosteroid use; and caregiver education with explicit thresholds for escalation.

PMID 42499403
Read full article →
PubMedProgress in neuro-psychopharmacology & biological psychiatry2026-07-24

Transdiagnostic medication-associated weight gain across five effectiveness trials: a harmonized longitudinal cohort analysis of antipsychotics, antidepressants, and mood stabilizers.

Serretti Alessandro A

Psychotropic-associated weight gain contributes to non-adherence and cardiometabolic morbidity, but antipsychotics, antidepressants, and mood stabilizers are rarely compared in a common longitudinal framework. We harmonized 4945 participants from five NIMH effectiveness trials: CATIE and ACLAIMS (schizophrenia; antipsychotics), CO-MED (major depression; three antidepressant regimens-escitalopram monotherapy, bupropion-escitalopram, and venlafaxine-mirtazapine), and STEP-BD and LiTMUS (bipolar disorder; mood stabilizers). Co-primary outcomes were cumulative clinically significant weight gain (≥7%; restricted to the 4436 participants with ≥1 post-baseline weight) and the early weight-change slope (6 months); ≥7% gain within a common 6-month window was an additional, observation-time-matched comparison. Models adjusted for baseline weight, age, and sex where applicable. Cumulative ≥7% gain occurred in 41% of antipsychotic, 29% of mood-stabilizer, and 16% of antidepressant-treated participants with a post-baseline weight (antipsychotic vs antidepressant OR 3.67, 95% CI 2.74-4.91); the cumulative proportions were similar across the two antipsychotic and the two mood-stabilizer trials. This cumulative difference partly reflects the longer follow-up and more frequent weight measurement in the antipsychotic trials: early weight-gain slopes did not differ significantly between antipsychotics and antidepressants, and within a common 6-month window no statistically significant difference in clinically significant gain was detected between the antipsychotic and antidepressant cohorts (OR 1.29, 95% CI 0.91-1.81, p = 0.148). Lower baseline weight predicted cumulative gain (p < 0.001) but was null for absolute (kg) weight gain (OR 1.002 per kg, p = 0.161), indicating it partly reflects the mathematics of a percentage-based threshold; younger age and male sex predicted faster early gain. In exploratory secondary analyses the antipsychotic trials showed serum-glucose increases, with a waist increase in CATIE. In these trial-defined class/diagnosis-regimen cohorts, the apparent antipsychotic excess was largely cumulative and associated with longer observation duration and more frequent measurement; within a common 6-month window no statistically significant difference in early weight gain was detected between the antipsychotic and antidepressant cohorts. Because drug class, diagnosis, and trial are aligned in this design, these differences should not be interpreted as an isolated drug-class effect. Younger patients-and, for proportional gain, leaner patients-warrant early metabolic monitoring across diagnoses.

PMID 42492718
Read full article →
PubMedmicroPublication biology2026-07-23

Evaluating Caenorhabditis elegans as a Toxicity Model for Reuptake Inhibitors.

Hernandez Christopher E CE, Van Stone Alexandra A, So Christopher C

Drug toxicity assessment is important for drug development. Here, we evaluated whether the invertebrate model Caenorhabditis elegans can be used to assess the toxicity of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Drug-induced non-responsiveness served as a functional measure of toxicity. Overall, responses did not consistently parallel those of mammals, although select trends were conserved. Escitalopram showed greater toxicity than citalopram, duloxetine was more toxic than milnacipran, and desvenlafaxine, but not venlafaxine, produced toxicity. These results suggest that C. elegans cannot replace mammalian testing, but may serve as a rapid and low-cost prescreening model.

PMID 42491588
Read full article →
PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-07-23

The IRE1-XBP1s Axis Drives Inflammatory Osteolysis by Regulating a 5-HT Dependent Endogenous Anti-Autophagy Mechanism.

Yang Pengchao P, Zhu Binxiang B, He Yuzhi Y, Tian Yang Y et al.

Inflammatory osteolysis arises from pro-inflammatory cytokine-driven osteoclast activation and disrupted bone remodeling equilibrium. The IRE1-XBP1s axis, a major unfolded protein response pathway, regulates cellular homeostasis, but its role in inflammatory osteoclastogenesis remained unexplored. Single-cell RNA-seq showed increased osteoclast precursor cells and activated IRE1-XBP1s in LPS-induced osteolysis. Inhibition of this axis reduced osteoclastogenesis and bone loss in vitro and in vivo. RNA-seq indicated that blocking IRE1-XBP1s suppressed Slc6a4 transcription, with gene set enrichment analysis confirming its role in 5-HT transport. Dual-luciferase assays and ChIP-PCR demonstrated XBP1s' direct transcriptional regulation targeting the Slc6a4 promoter. The 5-HT transporter inhibitor escitalopram also inhibited osteoclastogenesis, highlighting the IRE1-XBP1s-Slc6a4 axis's importance. Notably, untargeted metabolomics suggested 5-HT inhibited intracellular 3-methyladenine (3MA) metabolism, a compound previously considered unnatural. HPLC-MS confirmed the presence of 3MA metabolism in inflammatory osteoclasts, and 3MA supplementation attenuated 5-HT-induced autophagy and osteoclast differentiation. Blocking the IRE1-XBP1s-Slc6a4 axis reduced pro-osteoclastogenic effects in inflammatory bone disease patient-derived PBMCs. This study demonstrates that IRE1-XBP1s inhibition alleviates inflammatory osteoclastogenesis and osteolysis via a 5-HT-dependent anti-autophagy mechanism, proposing this pathway as a therapeutic target for inflammatory bone loss.

PMID 42490691
Read full article →
PubMedSante mentale au Quebec2026-07-23

Schizo-obsessive disorder in a South Asian context: A case report highlighting religious obsessions and psychosis.

Yusuf Rahemeen R, Munir Rabia R, Nizami Asad Tamizuddin AT, Malik Ifrah Javed IJ et al.

Background The co-occurrence of schizophrenia and obsessive-compulsive disorder has attracted increasing clinical and research attention, yet it is not recognised as a distinct diagnostic entity in current psychiatric classification systems. This overlap is associated with greater symptom severity, increased suicide risk, and poorer treatment outcomes. Despite its clinical relevance, reports from South Asia remain scarce. This case contributes regional data and supports the conceptualisation of a schizo-obsessive subtype, challenging existing nosological boundaries. Case Presentation We report the case of a 29-year-old man with progressive social withdrawal, persecutory beliefs, and second-person auditory hallucinations. Symptoms emerged insidiously following a relational stressor and included religious-themed command hallucinations leading to a suicide attempt. Concurrently, he experienced intrusive, ego-dystonic religious images during prayer, accompanied by compulsive hand-washing and mental neutralising rituals related to blasphemous fears. There was no history of prior psychiatric treatment, substance use, or neurological illness. Mental state examination and structured assessments supported a diagnosis of schizophrenia with co-morbid moderate obsessive-compulsive symptoms. Treatment with olanzapine, followed by escitalopram, resulted in symptomatic improvement. Exposure and response prevention therapy showed sustained benefit in follow-up. Conclusions This case highlights the clinical importance of recognising co-occurring schizophrenia and obsessive-compulsive symptoms, regardless of medication or neurological issues. Prominent religious themes suggest considering cultural and religious contexts, especially in highly religious societies. As a rare detailed report from Pakistan, it provides valuable regional data and indicates schizo-obsessive presentations may be under-recognised in South Asia. Recognising this profile can improve diagnosis, foster culturally sensitive treatments, and encourage further research.

PMID 42490708
Read full article →
PubMedFrontiers in cardiovascular medicine2026-07-22

Effect of anti-anxiety therapy on the prognosis of patients with atrial fibrillation and anxiety: a 2 × 2 factorial randomized controlled trial.

Qin Zuoan Z, Lu Xuelin X, Li Ying Y, Ge Liangqing L

Atrial fibrillation (AF) and anxiety frequently co-occur, significantly impairing quality of life (QoL) and potentially worsening prognosis. However, integrated psychological management in AF care remains insufficient, with scarce evidence on combined pharmacotherapy and psychological interventions. This single-center, randomized controlled trial employed a 2 × 2 factorial design to evaluate the efficacy of combined anti-anxiety therapy [escitalopram and Cognitive Behavioral Therapy (CBT)] in 120 patients with AF and anxiety (GAD-7 ≥ 10). Participants were allocated to one of four groups: Drug Therapy, Psychological Intervention (CBT), Combination (Drug + CBT), or Control (routine care). The primary endpoint was the change in QoL (SF-36 questionnaire) at 3 and 6 months, and the secondary endpoint was the incidence of Major Adverse Cardiovascular Events (MACE). A total of 117 patients completed the follow-up. At 6 months, significant improvements were observed in the Role-Physical (RP), General Health (GH), Vitality (VT), and Social Functioning (SF) domains of the SF-36 in the intervention groups compared to the control group (all P < 0.01). Factorial analysis of the GH score change confirmed significant main effects for both psychological intervention (P < 0.001) and drug therapy (P = 0.011), with no significant interaction, indicating additive benefits. The Combination group also demonstrated a significantly lower overall incidence of MACE at 6 months compared to the Control group (36.67% vs. 70.00%, P = 0.003). This study demonstrates that combined anti-anxiety pharmacotherapy and psychological therapy improves QoL and reduces cardiovascular risk in patients with AF and anxiety.

PMID 42483461
Read full article →

+8257 more articles available with a free account

Sign up free to view all articles →

Ask about escitalopram + clonazepam